2 completed, 1 active not recruiting. 3 Phase 1, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Completed 2, Active not recruiting 1 |
| Phase 2 | 1 | Completed 1 |
Follow OnKure, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| First-in-Human Study of OKI-219 in Advanced Solid Tumors and Advanced Breast Cancer OKI-219, Fulvestrant, Trastuzumab - Advanced Cancer, Breast Cancer | Phase 1 | Active not recruiting | OnKure, Inc. | 200 | 2024-02-26 | 2026-07-06 |
| NAUTILUS: OKI-179 Plus Binimetinib in Patients with Advanced Solid Tumors in the RAS Pathway (Phase 1b) and NRAS-mutated Melanoma (Phase 2) OKI-179 + binimetinib - RAS Mutation, NRAS Gene Mutation | Phase 1 / Phase 2 | Completed | OnKure, Inc. | 36 | 2022-05-11 | 2025-03-07 |
| A Study of OKI-179 in Patients With Solid Tumors OKI-179 - Advanced Solid Tumors | Phase 1 | Completed | OnKure, Inc. | 34 | 2019-05-08 | 2021-12-06 |
Breast Neoplasms (1) · Melanoma (1)
Fulvestrant (1) · Trastuzumab (1) · binimetinib (1) · ribociclib (1) · tucatinib (1)
United States (3) · Belgium (1) · France (1) · Italy (1) · South Korea (1) · Spain (1)
Jennifer Diamond, MD (1) · Ryan Sullivan, MD (1)